Anti-Acne Drugs in Phase 1 and 2 Clinical Trials

The document reviewed phase 1 and 2 clinical trials for new anti-acne drugs, highlighting the need for novel treatments due to issues like microbial resistance and adverse drug profiles. The trials primarily focused on topical agents with sebosuppressive, antimicrobial, or anti-inflammatory properties, including compounds like olumacostat glasaretil and cortexolone 17α-propionate. Systemic treatments under investigation included finasteride and leukotriene B4 inhibitors, though no significant breakthroughs were anticipated. Future developments might target skin microbiota modulation. The authors disclosed various industry affiliations and funding sources but stated no additional conflicts of interest.